Ryan Lynch, Treasurer, Senior Vice President of Finance and Chief Accounting Officer of Crescent BioPharma, Inc. (NASDAQ:CBIO), filed a Form 4 on September 18, 2026, disclosing an automatic sale of ordinary shares on September 16, 2026, to satisfy tax withholding obligations tied to vesting restricted stock units.

Key Highlights

  • Shares sold: 240 ordinary shares were disposed of on September 16, 2026, with transaction code "S" (sale).
  • Weighted average price: $17.90 per share, with individual transactions ranging from $17.10 to $19.17, inclusive.
  • Purpose of sale: Shares were automatically sold solely to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted on December 15, 2025.
  • Rule 10b5-1 plan: The sales were effected pursuant to a Rule 10b5-1 instruction adopted by Lynch on February 25, 2026.
  • Remaining ownership: Following the transaction, Lynch directly beneficially owns 13,631 ordinary shares.
  • Signed by: Barbara Bispham Hale, as attorney-in-fact for Ryan Lynch, on September 18, 2026.

Ryan Lynch RSU Tax Sale Details at Crescent BioPharma

According to the filing, Ryan Lynch, identified in the remarks as Treasurer, Senior Vice President of Finance and Chief Accounting Officer of Crescent BioPharma, Inc., disposed of 240 ordinary shares on September 16, 2026. The filing states the shares were "automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025."

The filing discloses that the reported price of $17.90 per share is a weighted average, with the actual transactions executed at prices ranging from $17.10 to $19.17, inclusive, across multiple transactions. Lynch, according to the filing, "undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."

The filing further notes that the sales were carried out under a Rule 10b5-1 instruction that Lynch adopted on February 25, 2026, "solely with the intent to cover taxes in connection with the vesting of the restricted stock units." The Form 4 also indicates the reporting person checked the box confirming the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Following the reported transaction, Lynch directly holds 13,631 ordinary shares, according to the filing.

What Was Disclosed

The filing reports a single disposition of 240 ordinary shares by a Crescent BioPharma officer on September 16, 2026, at a weighted average price of $17.90, conducted automatically under a Rule 10b5-1 plan to cover RSU-related tax obligations, leaving the officer with 13,631 shares directly held.